Bank of America’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,500
| Closed | -$3.65M | – | 8166 |
|
|
2025
Q3 | $3.65M | Hold |
6,500
| – | – | ﹤0.01% | 4304 |
|
|
2025
Q2 | $3.41M | Sell |
6,500
-16,300
| -71% | -$9.1M | ﹤0.01% | 4279 |
|
|
2025
Q1 | $14.5M | Sell |
22,800
-39,300
| -63% | -$27M | ﹤0.01% | 2785 |
|
|
2024
Q4 | $44.2M | Sell |
62,100
-2,500
| -4% | -$2.1M | ﹤0.01% | 1609 |
|
|
2024
Q3 | $67.9M | Buy |
64,600
+5,300
| +9% | +$5.9M | 0.01% | 1324 |
|
|
2024
Q2 | $62.3M | Buy |
59,300
+200
| +0.3% | +$194K | 0.01% | 1311 |
|
|
2024
Q1 | $56.9M | Sell |
59,100
-4,300
| -7% | -$4.09M | 0.01% | 1384 |
|
|
2023
Q4 | $55.7M | Buy |
63,400
+8,700
| +16% | +$7.16M | 0.01% | 1293 |
|
|
2023
Q3 | $45M | Buy |
54,700
+4,300
| +9% | +$3.38M | 0.01% | 1350 |
|
|
2023
Q2 | $36.2M | Sell |
50,400
-56,800
| -53% | -$43.8M | ﹤0.01% | 1547 |
|
|
2023
Q1 | $88.1M | Buy |
107,200
+106,600
| +17,767% | +$80.4M | 0.01% | 1013 |
|
|
2022
Q4 | $433K | Sell |
600
-15,000
| -96% | -$11.1M | ﹤0.01% | 5485 |
|
|
2022
Q3 | $10.7M | Buy |
15,600
+15,100
| +3,020% | +$9.5M | ﹤0.01% | 2549 |
|
|
2022
Q2 | $296K | Hold |
500
| – | – | ﹤0.01% | 5813 |
|
|
2022
Q1 | $349K | Sell |
500
-2,100
| -81% | -$1.33M | ﹤0.01% | 6074 |
|
|
2021
Q4 | $1.64M | Buy |
2,600
+1,100
| +73% | +$676K | ﹤0.01% | 4756 |
|
|
2021
Q3 | $908K | Sell |
1,500
-102,300
| -99% | -$63.5M | ﹤0.01% | 5174 |
|
|
2021
Q2 | $58M | Buy |
103,800
+47,700
| +85% | +$24.2M | 0.01% | 1274 |
|
|
2021
Q1 | $26.5M | Buy |
56,100
+29,200
| +109% | +$14.2M | ﹤0.01% | 1793 |
|
|
2020
Q4 | $13M | Buy |
+26,900
| New | +$14.5M | ﹤0.01% | 2268 |
|
|
2020
Q1 | – | Sell |
-31,600
| Closed | -$11.9M | – | 7177 |
|
|
2019
Q4 | $11.9M | Buy |
31,600
+30,500
| +2,773% | +$10.3M | ﹤0.01% | 2384 |
|
|
2019
Q3 | $305K | Sell |
1,100
-1,100
| -50% | -$326K | ﹤0.01% | 5404 |
|
|
2019
Q2 | $689K | Sell |
2,200
-5,100
| -70% | -$1.7M | ﹤0.01% | 4845 |
|
|
2019
Q1 | $3M | Sell |
7,300
-3,500
| -32% | -$1.44M | ﹤0.01% | 3648 |
|
|
2018
Q4 | $4.03M | Buy |
10,800
+700
| +7% | +$256K | ﹤0.01% | 3227 |
|
|
2018
Q3 | $4.08M | Buy |
10,100
+300
| +3% | +$114K | ﹤0.01% | 3382 |
|
|
2018
Q2 | $3.38M | Sell |
9,800
-12,600
| -56% | -$3.94M | ﹤0.01% | 3524 |
|
|
2018
Q1 | $7.71M | Buy |
22,400
+14,100
| +170% | +$4.9M | ﹤0.01% | 2667 |
|
|
2017
Q4 | $3.12M | Sell |
8,300
-6,900
| -45% | -$2.79M | ﹤0.01% | 3559 |
|
|
2017
Q3 | $6.8M | Buy |
15,200
+13,000
| +591% | +$6.19M | ﹤0.01% | 2898 |
|
|
2017
Q2 | $1.08M | Sell |
2,200
-46,700
| -96% | -$20.4M | ﹤0.01% | 4381 |
|
|
2017
Q1 | $18.9M | Buy |
48,900
+43,800
| +859% | +$16.2M | ﹤0.01% | 1796 |
|
|
2016
Q4 | $1.87M | Buy |
5,100
+1,900
| +59% | +$723K | ﹤0.01% | 3825 |
|
|
2016
Q3 | $1.29M | Hold |
3,200
| – | – | ﹤0.01% | 3978 |
|
|
2016
Q2 | $1.12M | Hold |
3,200
| – | – | ﹤0.01% | 4091 |
|
|
2016
Q1 | $1.15M | Hold |
3,200
| – | – | ﹤0.01% | 4013 |
|
|
2015
Q4 | $1.74M | Sell |
3,200
-5,000
| -61% | -$2.71M | ﹤0.01% | 3922 |
|
|
2015
Q3 | $3.81M | Buy |
8,200
+5,000
| +156% | +$2.69M | ﹤0.01% | 3158 |
|
|
2015
Q2 | $1.63M | Buy |
+3,200
| New | +$1.56M | ﹤0.01% | 3667 |
|
|
2015
Q1 | – | Sell |
-14,700
| Closed | -$6.03M | – | 7458 |
|
|
2014
Q4 | $6.03M | Buy |
14,700
+500
| +4% | +$197K | ﹤0.01% | 2382 |
|
|
2014
Q3 | $5.12M | Buy |
14,200
+1,200
| +9% | +$402K | ﹤0.01% | 2555 |
|
|
2014
Q2 | $3.67M | Sell |
13,000
-28,500
| -69% | -$8.45M | ﹤0.01% | 2831 |
|
|
2014
Q1 | $12.5M | Buy |
41,500
+39,100
| +1,629% | +$12M | ﹤0.01% | 1616 |
|
|
2013
Q4 | $661K | Sell |
2,400
-4,500
| -65% | -$1.29M | ﹤0.01% | 4504 |
|
|
2013
Q3 | $2.16M | Buy |
6,900
+3,800
| +123% | +$1,000K | ﹤0.01% | 3201 |
|
|
2013
Q2 | $697K | Buy |
+3,100
| New | +$722K | ﹤0.01% | 4414 |
|
Other funds holding REGN
VCM
N
Bank of America's REGN Position: Q1 2026 in Review
Bank of America increased its Regeneron Pharmaceuticals (REGN) stake by 2.8% in Q1 2026, buying an estimated $24.6M and bringing the position to 1,189,584 shares worth $919M. The position accounts for 0.07% of the portfolio, ranked #263.
Bank of America first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.04B in Q3 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Bank of America held 1,189,584 shares of Regeneron Pharmaceuticals worth $919M as of Q1 2026.
- Bank of America bought 32,158 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $24.6M.
- Regeneron Pharmaceuticals made up 0.07% of Bank of America's portfolio in Q1 2026, its #263 holding.
- Bank of America first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Regeneron Pharmaceuticals position peaked at $1.04B in Q3 2024.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.